Roivant Sciences Stock: The Balance Sheet Has Become A Strategic Weapon (NASDAQ:ROIV)
· seekingalpha.com
Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma. Check out why ROIV stock is a buy.
I have developed a bull thesis on Roivant Sciences ( ROIV ) because of a shift in the company's basic failure mode. Historically, the major concerns for investo...